Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Pharmaceuticals  // Browsing posts in Pharmaceuticals

Buprenorphine Opioid Addiction Treatment Idea Proposal

Buprenorphine Opioid Addiction Treatment Idea Proposal

Will long acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Report Available: April 8, 2016   Blueshift’s initial research shows that addiction to opioids has skyrocketed to the point of being an epidemic. Current available treatment options face numerous challenges including frequent dosing, poor adherence, high incidence of relapse, and misuse. […]

Read more...

Blockbuster Sales Not in Store for Depomed’s Nucynta

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as the company takes on OxyContin among acute pain patients and Lyrica and Cymbalta in neuropathic pain patients? Companies: DEPO, HZNP, JNJ, LLY, PFE, TSE:ENL By: David Franklin Click here to download the report (.pdf)   Summary of Findings Depomed Inc.’s (DEPO) Nucynta and Nucynta […]

Read more...

Depomed Idea Proposal (DEPO)

Depomed Idea Proposal (DEPO)

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as it takes on OxyContin with acute pain patients and Lyrica/Cymbalta with neuropathic pain patients? Report Available: Oct. 29, 2015   Blueshift’s initial research shows DEPO sold $57 million worth of painkiller Nucynta in its first quarter and believes it has the potential to reach $1 […]

Read more...

Seres’ SER-109 Likely Will Be the First Microbiome Therapy to Market

Research Question: Will Seres Therapeutics’ SER-109 be the first approved and best microbiome therapy to treat Clostridium difficile infections? Companies: ALIOF/VTX:ATLN, MCRB, MRK, NVS, PFE, SHPG, SNY, SYN By: David Franklin Click here to download the report (.pdf)   Summary of Findings Seres Therapeutics Inc.’s (MCRB) Phase 2 drug, SER-109, is expected to be the first […]

Read more...

Seres Therapeutics Idea Proposal

Seres Therapeutics Idea Proposal

Research Question: Will Seres Therapeutics’ SER-109 be the first approved and best microbiome therapy to cure Clostridium difficile infection? Report Available: October 1, 2015   Blueshift’s initial research shows MCRB’s SER-109 garnering much support from Wall Street and the FDA,which should hasten its time to market. Given SER-109’s exceptional 97% cure rate for the infectious CDI, MCRB hopes […]

Read more...

Well-Received Zarxio Will Pave Way to Eventual Wide Biosimilar Adoption

Research Question: Will Sandoz’s (Novartis) Zarxio, the first biosimilar approved by the FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilars? Companies: AMGN, BOM:500359, EPRS, ESRX, HSP, KOSDAQ:068270, NVS, MRK, PFE By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Adoption of […]

Read more...

Biosimilars Whisper

Biosimilars Whisper

Research Question: Will Novartis’ Sandoz Zarxio, the first biosimilar approved by the U.S. FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilar drugs? Companies Covered: Amgen (AMGN), Novartis AG (NVS), Hospera (HSP), Celltrion (068270.KQ), Merck (MRK), Express Scripts (ESRX) Report Available: May 21, 2015   Blueshift’s […]

Read more...

Teva’s Long-Term Success Will Depend on Strategic Acquisitions

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies: ACT, AZN, BIIB, HSP, MYL, NVS, PFE, SLXP, TSE:VRX, TLV:TEVA By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Ten sources who commented offered mixed responses on the likelihood of Teva Pharmaceutical Industries […]

Read more...

Teva Pharmaceuticals Whisper

Teva Pharmaceuticals Whisper

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies Covered: Teva Pharmaceuticals (TEVA), Novartis AG (NVS), Mylan (MYL) Report Available: March 25, 2015   Blueshift’s initial research shows Teva’s highly profitable MS drug, Copaxone, is nearing the patent cliff, though its patent-protected reformulation of […]

Read more...

Current Exparel Users Satisfied; FDA Concerns Create Potential Hurdles

Research Question: Has the FDA warning letter negatively affected use of Pacira Pharmaceutical’s Exparel? Companies: HCA, HYH, PCRX By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Two distinct schools of thought on the impact of a September FDA warning letter to Pacira Pharmaceuticals Inc. (PCRX) emerged in this report. Industry specialists […]

Read more...